Ibuprofen product-specific bioequivalence guidance

Current version

Adopted guideline

Adopted guideline enters into effect 01/12/2018 - see below

Reference numberEMA/CHMP/356876/2017
Published26/06/2018
Effective from01/12/2018
KeywordsBioequivalence, generics, ibuprofen
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of ibuprofen.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration

Document history

First version
Current version

PDF iconAdopted guideline


PDF iconDraft guideline

Published: 26/06/2018
Effective from: 01/12/2018

Published: 01/08/2016

Related content


How useful was this page?

Add your rating